Sensory systems

Color Blind Women Face Unique Challenges, EnChroma Study Finds

Retrieved on: 
Monday, September 6, 2021
Biotechnology, Pharmaceutical, Optical, General Health, Health, Medical Devices, Genetics, Other Health, Vision, Sensory systems, Nervous system, Color vision, Image processing, Agnosia, Color blindness, Ophthalmology, Visual impairment, EnChroma, Color, Sunglasses

Today, on International Color Blindness Awareness Day, EnChroma creators of glasses for color blindness released the results of a survey detailing the numerous challenges and frustrations encountered by color blind women.

Key Points: 
  • Today, on International Color Blindness Awareness Day, EnChroma creators of glasses for color blindness released the results of a survey detailing the numerous challenges and frustrations encountered by color blind women.
  • Color Vision Deficiency (CVD) is relatively rare in women, with one in 200 (.5%) color blind; roughly 20 million worldwide.
  • View the full release here: https://www.businesswire.com/news/home/20210906005027/en/
    Normal Color Vision and Color Vision Deficient Views (Graphic: Business Wire)
    Key findings of the survey include that 75% of women experience skepticism in school that they are actually color blind; two-thirds were teased at school for being color blind; nearly half say they face more challenges than color blind men; and 81% believe they endured extra struggles or delays before doctors, educators or their parents suspected they might be color blind.
  • Half of color blind women report their parents were surprised to learn theyre color blind.

Topcon Healthcare to Partner with RetInSight

Retrieved on: 
Tuesday, August 3, 2021
Data management, Health, Medical devices, Technology, Software, Optical, Biotechnology, Branches of biology, Vision, Sensory systems, Topcon, Retina, Geographic atrophy

Topcon Healthcare of Oakland, NJ, a leading provider of medical devices and software solutions for the global eye care community, announced today that it will partner with RetInSight GmbH, a developer of retina AI solutions based in Vienna, Austria.

Key Points: 
  • Topcon Healthcare of Oakland, NJ, a leading provider of medical devices and software solutions for the global eye care community, announced today that it will partner with RetInSight GmbH, a developer of retina AI solutions based in Vienna, Austria.
  • RetInSights novel, proprietary algorithms aim to support clinicians in the detection, quantification, and monitoring of key retinal biomarkers including retinal fluid and geographic atrophy lesions.
  • With this collaboration, Topcon and RetInSight hope to extend retinal fluid detection and monitoring to primary eye care providers, facilitating co-management of patients.
  • We are very pleased to add this powerful module to our already robust Harmony clinical data management solution and to our world-leading OCTs, said Tobias Kurzke, Director of Product Management for Topcon Healthcare.

AGTC to Participate at Upcoming Investor Conferences

Retrieved on: 
Monday, August 2, 2021
Vision, Channelopathies, Nervous system, Sensory systems, Blindness, Retinitis pigmentosa, Wedbush Securities, Achromatopsia, Retinitis, Applied Genetic Technologies Corporation

2021 Wedbush PacGrow Healthcare Virtual Conference (August 10-11, 2021)

Key Points: 
  • 2021 Wedbush PacGrow Healthcare Virtual Conference (August 10-11, 2021)
    Ms. Washer will participate in a panel discussion entitled: Only Have Eyes For You - Ophthalmic Gene Therapy at 8:00 a.m.
  • Audio webcasts of the presentations at the Wedbush and H.C. Wainwright conferences can be accessed by visiting http://ir.agtc.com/events-and-presentations .
  • AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM B3 and ACHM A3).
  • AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.

Clearside Biomedical to Report Second Quarter 2021 Financial Results and Provide Corporate Update on Tuesday, August 10, 2021

Retrieved on: 
Tuesday, July 27, 2021
Visual system, Anatomy, Vision, Sensory systems, Choroid, Retina, Eye disease, Macula of retina

Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

Key Points: 
  • Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.
  • The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations .
  • Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases.
  • Clearsides proprietary SCS Microinjector targets the suprachoroidal space (SCS) and offers unique access to the macula, retina and choroid where sight-threatening disease often occurs.

Seventy-Five Percent of Color Blind People Experience Challenges at Work, EnChroma Study Finds

Retrieved on: 
Monday, July 26, 2021
Optical, Professional services, Health, Human resources, Vision, Color vision, Nervous system, Sensory systems, Ophthalmology, Agnosía, Color blindness, Visual impairment, Enchroma, Glasses, Color, Visual perception

View the full release here: https://www.businesswire.com/news/home/20210726005726/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210726005726/en/
    View of color wires as they appear to someone with color vision deficiency and to someone with standard color vision.
  • From April to May 2021, 810 color blind people responded to an EnChroma survey measuring the effect of their condition on the job, with 688 relaying anecdotes from their work experiences.
  • Color blind people are just as successful and productive as any employee, but they can use a hand to reduce the everyday nuisances and obstacles they experience related to color in the workplace.
  • Consider making reasonable workplace accommodation assistive tools available to color blind employees, like EnChroma glasses for color blindness.

Nevro Announces FDA Approval of its 10 kHz High Frequency Spinal Cord Stimulation Therapy for Treatment of Chronic Pain Associated with Painful Diabetic Neuropathy (PDN)

Retrieved on: 
Monday, July 19, 2021
Branches of biology, Neuroscience, Neurotechnology, Neurophysiology, Pain, Acute pain, Sensory systems, Neuromodulation, Spinal cord stimulator, Peripheral neuropathy, Spinal cord, Neurostimulation

This approval is specific to Nevro's unique 10 kHz stimulation, and Nevro now has the only spinal cord stimulation system approved by the FDA with a specific indication to treat PDN.

Key Points: 
  • This approval is specific to Nevro's unique 10 kHz stimulation, and Nevro now has the only spinal cord stimulation system approved by the FDA with a specific indication to treat PDN.
  • Study participants demonstrated significantly improved and sustained outcomes with 10 kHz Spinal Cord Stimulation (SCS), including substantial, sustained pain relief and improved health-related quality of life.
  • Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain.
  • Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy: ARandomized Clinical Trial.JAMA Neurol.2021 Jun 1;78(6):687-698. doi:10.1001/jamaneurol.2021.0538.

OpRegen® Data Update to Be Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.

Retrieved on: 
Tuesday, July 13, 2021
Biotechnology, Health, Pharmaceutical, Optical, Clinical trials, Vision, Sensory systems, Nervous system, Optometry, Visual system, Retina, Visual acuity, Visual perception, OpRegen, Age-Related Macular Degeneration, Lineage Cell Therapeutics, Inc., OPREGEN, AGE-RELATED MACULAR DEGENERATION, LINEAGE CELL THERAPEUTICS, INC.

The Retina Society was founded in 1968 exclusively for educational and scientific purposes concerning the diagnosis, care and treatment of diseases and injuries to the retina.

Key Points: 
  • The Retina Society was founded in 1968 exclusively for educational and scientific purposes concerning the diagnosis, care and treatment of diseases and injuries to the retina.
  • For more information on the Retina Society or its annual scientific meeting, please visit https://www.retinasociety.org/ or follow the association on Twitter @RetinaSociety .
  • The first 3 cohorts enrolled only legally blind patients with Best Corrected Visual Acuity (BCVA) of 20/200 or worse.
  • The fourth cohort enrolled 12 better vision patients (BCVA from 20/65 to 20/250 with smaller mean areas of GA).

EnChroma Launches World’s First Safety Glasses for Color Blindness

Retrieved on: 
Monday, July 12, 2021
Optical, Health, Medical devices, Vision, Color vision, Nervous system, Sensory systems, Ophthalmology, Eyewear, Corrective lenses, Glasses, Protective gear, Enchroma, Color blindness, Visual impairment

EnChroma, Inc. creators of glasses for color blindness today announced the first safety glasses for the estimated 350 million people in the world who are color blind.

Key Points: 
  • EnChroma, Inc. creators of glasses for color blindness today announced the first safety glasses for the estimated 350 million people in the world who are color blind.
  • The new line of EnChroma Safety Glasses are designed to help people with red-green color blindness overcome daily frustrations and obstacles in the workplace related to correctly identifying and interpreting colors.
  • The glasses address most types of red-green color blindness and are available at enchroma.com and through select EnChroma Authorized Retailers worldwide.
  • Based in Berkeley, Calif., EnChroma produces leading-edge eyewear for color blindness and low vision, and other solutions for color vision, sold online and through Authorized Retailers worldwide.

AGTC to Host Virtual R&D Day on July 22, 2021

Retrieved on: 
Thursday, July 8, 2021
Vision, Channelopathies, Nervous system, Sensory systems, Blindness, Retinitis pigmentosa, Achromatopsia, Applied Genetic Technologies Corporation

We look forward to taking a deeper dive into this data during our R&D Day and discussing preparations for late-stage development of our ACHM and XLRP candidates.

Key Points: 
  • We look forward to taking a deeper dive into this data during our R&D Day and discussing preparations for late-stage development of our ACHM and XLRP candidates.
  • AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases.
  • AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM B3 and ACHM A3).
  • AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.

The BeHear.ACCESS hearing amplification headset gains hyper-advanced hearing aid functionality

Retrieved on: 
Tuesday, July 6, 2021
Otology, Nervous system, Otorhinolaryngology, Audiology, Sensory systems, Hearing aid, Hearing loss, Hearing

ACCESS is a hearable that provides personalized hearing amplification users can self-tune in real time via the companion app.

Key Points: 
  • ACCESS is a hearable that provides personalized hearing amplification users can self-tune in real time via the companion app.
  • This already sophisticated product received an upgrade that added hyper-advanced hearing aid functionality: 3 features that are normally found only in top-of-the-line hearing aids.
  • Additionally, people with unilateral or "single-sided" hearing will benefit from new CROS/BiCROS functionality, which transfers sounds from the non-hearing side to the hearing ear.
  • When activated, the function takes effect for all ACCESS hearing modes: Personal Hearing, Mobile Calls, and Audio Play.